Insights Blog
Explore our thought leadership insights, as life science technologies evolve and accelerate.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
DeciBio Q&A
Clinical Diagnostics
Explainable, Unbiased AI and Computational Systems Pathology: Q&A with Dusty Majumdar and Chakra Chennubhotla of SpIntellx
DeciBio interviews Dusty Majumdar and Chakra Chennubhotla, CEO and CTO at SpIntellx.
September 22, 2022
DeciBio Q&A
Clinical Diagnostics
Explainable, Unbiased AI and Computational Systems Pathology: Q&A with Dusty Majumdar and Chakra Chennubhotla of SpIntellx
DeciBio interviews Dusty Majumdar and Chakra Chennubhotla, CEO and CTO at SpIntellx.
September 22, 2022
Digital Pathology
Blog Article
Clinical Diagnostics
Oncologist Perspectives on the Most Exciting Advancements in Precision Medicine
DeciBio conducted a pulse survey with 8 U.S. oncologists to ascertain what precision oncology advancements excite them the most.
September 21, 2022
Blog Article
Clinical Diagnostics
Oncologist Perspectives on the Most Exciting Advancements in Precision Medicine
DeciBio conducted a pulse survey with 8 U.S. oncologists to ascertain what precision oncology advancements excite them the most.
September 21, 2022
Precision Medicine
Immuno-Oncology
Next-Generation Therapeutics
DeciBio Q&A
Clinical Diagnostics
Digital Pathology for Biomarker Development: Decibio’s Q&A with Chan-Young Ock of Lunit
Decibio interviews Dr. Chan-Young Ock of recently IPO’d digital pathology firm, Lunit.
September 21, 2022
DeciBio Q&A
Clinical Diagnostics
Digital Pathology for Biomarker Development: Decibio’s Q&A with Chan-Young Ock of Lunit
Decibio interviews Dr. Chan-Young Ock of recently IPO’d digital pathology firm, Lunit.
September 21, 2022
Clinical Diagnostics
Research Tools
AI / Machine Learning
Digital Pathology
Immuno-Oncology
In The Press
Pharma & Biotech
Mark a Course for the Future – Biomarkers in Cancer Immunotherapy
Here we explore how biomarkers are driving the immuno-oncology landscape. We dive into cutting-edge biomarker research and the challenges facing the field.
September 15, 2022
In The Press
Pharma & Biotech
Mark a Course for the Future – Biomarkers in Cancer Immunotherapy
Here we explore how biomarkers are driving the immuno-oncology landscape. We dive into cutting-edge biomarker research and the challenges facing the field.
September 15, 2022
Biomarkers
Immuno-Oncology
Newsletter Update
Clinical Diagnostics
Liquid Biopsy | August Roundup
Take a look at DeciBio’s in-depth recap of strategic liquid biopsy industry activity
September 6, 2022
Newsletter Update
Clinical Diagnostics
Liquid Biopsy | August Roundup
Take a look at DeciBio’s in-depth recap of strategic liquid biopsy industry activity
September 6, 2022
Liquid Biopsy
Newsletter Update
Pharma & Biotech
Next-Generation Therapeutics | August Roundup
August was a month that had some significant new therapeutic approvals as well as company launches, in addition to several financing rounds and partnerships. Read below to find out more about these new key developments.
September 1, 2022
Newsletter Update
Pharma & Biotech
Next-Generation Therapeutics | August Roundup
August was a month that had some significant new therapeutic approvals as well as company launches, in addition to several financing rounds and partnerships. Read below to find out more about these new key developments.
September 1, 2022
Next-Generation Therapeutics
Precision Medicine is evolving at a rapid pace
Discover how we can help
Get in Touch
© DeciBio 2023 | All rights reserved